Article
A New Hope in Advanced Lung Cancer
Combining erlotinib with SBRT more than doubled the survival time of stage 4 lung cancer patients.
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.
The combination of the chemotherapy regimen, erlotinib, with stereotactic body radiation therapy, known as SBRT, improved overall survival time to 20 months compared to historic 6- to 9-month survival times among erlotinib-only treated patients. The combination improved progression free survival — the time without the reappearance of cancer − from the historical two to four months to 14.7 months for similarly selected lung cancer patients.
Read the complete press release: http://bit.ly/1tKtWga
Source: UT Southwestern
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
